Gesynta Pharma reaches 50% patient enrollment milestone in Phase 2 endometriosis trial
June 18, 2026 | 15:05
Gesynta Pharma has announced that 50% of the target 190 patients have been randomized in its Phase 2 clinical proof-of-concept NOVA trial of vipoglanstat for endometriosis.
Mobile Version